Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Antiviral Therapy Inmanagement of Covid-19: A Systematic Review on Current Evidence Publisher



Yousefifard M1 ; Zali A2 ; Ali KM3 ; Neishaboori AM1 ; Zarghi A4 ; Hosseini M5, 6 ; Safari S7, 8
Authors
Show Affiliations
Authors Affiliations
  1. 1. Physiology Research Center, Iran University ofMedical Sciences, Tehran, Iran
  2. 2. Functional Neurosurgery Research Center, Shohada Tajrish Neurosurgical Comprehensive Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. College of Medicine, University of Sulaimani, Sulaimani, Iraq
  4. 4. Department of Medicinal Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  5. 5. Pediatric Chronic Kidney Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  8. 8. Emergency Department, Shohadye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Archives of Academic Emergency Medicine Published:2020


Abstract

Background: The purpose of the current systematic review is to evaluate the efficacy of antiviral therapies in treatment of COVID-19. In addition, clinical trials on the efficacy of antiviral therapies in the management of Severe Acute Respiratory Syndrome coronavirus (SARS-Cov) or Middle East Respiratory Syndrome coronavirus (MERS-CoV) have also been reviewed, in order to identify potential treatment options for COVID-19. Method: An extensive search was performed in Medline, Embase, Scopus, Web of Science and CENTRAL databases until the end of March 15, 2020. Two independent researchers performed the screening, and finally the related studies were included. Results: Only one clinical trial on the efficacy of antiviral therapy in management of COVID-19 was found. The results depicted that adding Lopinavir-Ritonavir to the standard treatment regimen of patients with severe COVID-19 has no benefits. Moreover, 21 case-series and case-report studies reported the prescription of antiviral agents in COVID-19, none of which can be used to determine the efficacy of antiviral therapies in confronting COVID-19. In addition, no clinical trials were found to be performed on the efficacy of antiviral agents in the management of SARS-CoV and MERS-CoV. Conclusion: The current evidence impede researchers from proposing an appropriate antiviral therapy against COVID-19, making the current situation a serious concern for international organizations such as World Health Organization (WHO). In the time of the current pandemic and future epidemics, organizations such asWHO should pursuemore proactive actions and plan well-designed clinical trials so that their results can be used in managing future epidemics. © 2020, Archives of Academic Emergency Medicine. All Rights Reserved.
Other Related Docs
14. Covid-19: A New Horizon in Congenital Heart Diseases, Frontiers in Pediatrics (2021)
18. Case Fatality Rate of Covid-19: A Systematic Review and Meta-Analysis, Journal of Preventive Medicine and Hygiene (2021)
23. Cancer Care Management During the Covid-19 Pandemic, Risk Management and Healthcare Policy (2020)
43. The Biochemical Parameters and Vitamin D Levels in Icu Patients With Covid-19: A Cross-Sectional Study, Endocrine# Metabolic and Immune Disorders - Drug Targets (2021)